Amcinonide
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Amcinonide
- Pharmacist Assessment Report
- Amcinonide: Potent topical corticosteroid → vulvar inverted follicular keratosis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Amcinonide: Potent topical corticosteroid → vulvar inverted follicular keratosis
One-Sentence Summary
Amcinonide is a potent topical corticosteroid used for inflammatory skin conditions. The TxGNN model predicts it may be effective for vulvar inverted follicular keratosis, with a score of 0.9982. There are currently no clinical trials and no publications supporting this specific direction, so this is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | vulvar inverted follicular keratosis |
| TxGNN Prediction Score | 0.9982 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for amcinonide. Based on its drug class, it is a potent (class II) topical corticosteroid. Drugs of this class reduce local inflammation and are widely used for inflammatory and proliferative skin disorders.
Inverted follicular keratosis is a benign keratinocytic lesion, which is related to other benign keratinocytic conditions where amcinonide-type corticosteroids are used. This similarity is likely what drives the model’s prediction.
However, inverted follicular keratosis is typically managed by excision, and no clinical or literature evidence exists for amcinonide in this condition. The mechanistic link is therefore speculative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02246714 | TARO-AMCINONIDE | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 44 potential interactions were identified, and the entries reviewed are all minor. They mainly involve glucose-lowering drugs (for example metformin, pioglitazone, sitagliptin, empagliflozin, semaglutide) and insulins, because corticosteroids can raise blood glucose.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (0.9982), but no clinical trial or publication studies this disease, so the evidence level is L5. Inverted follicular keratosis is usually treated surgically, which weakens the rationale for a topical corticosteroid.
To proceed, the following is needed:
- A systematic literature review for topical corticosteroid use in inverted follicular keratosis
- Mechanism of action data for amcinonide
- Health Canada package insert warnings and contraindications
- Review of the higher-ranked, better-supported lichen planus predictions as alternative candidates
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.